Crossref

1. New use of an old drug: chloroquine reduces viral and ALT levels in HCV non-responders (a randomized, triple-blind, placebo-controlled pilot trial)

- Payam Peymani

- Behzad Yeganeh

- Siamak Sabour

- Bita Geramizadeh

- Mohammad Reza Fattahi

- Hossein Keyvani

- Negar Azarpira

- Kevin M. Coombs

- Saied Ghavami

- Kamran B. Lankarani

2. Next Steps Toward Eradication of Hepatitis C in the Era of Direct Acting Antivirals

- Khashayar Hesamizadeh

- Heidar Sharafi

- Mohammad Saeid Rezaee-Zavareh

- Bita Behnava

- Seyed Moayed Alavian

3. Occult HCV Infection: The Current State of Knowledge

- Mohammad Saeid Rezaee-Zavareh

- Reza Hadi

- Hamidreza Karimi-Sari

- Mohammad Hossein Khosravi

- Reza Ajudani

- Fardin Dolatimehr

- Mahdi Ramezani-Binabaj

- Seyyed Mohammad Miri

- Seyed Moayed Alavian

4. A Cost-Utility Analysis of Different Antiviral Medicine Regimens in Patients With Chronic Hepatitis C Virus Genotype 1 Infection

- Seyed Moayed Alavian

- Shekoufeh Nikfar

- Abbas Kebriaeezadeh

- Farhad Lotfi

- Ehsan Sanati

- Mohsen Rezaei Hemami

- Khosro Keshavarz

5. Cost-utility Analysis of Second-generation Direct-acting Antivirals for Hepatitis C

- Zahra Goudarzi

- Abdollah Poursamad

- Iman Karimzadeh

- Nahid Jallaly

- Khosro Keshavarz

- Seyed Moayed Alavian